Vertex Pharmaceuticals (VX1d)
FRA • Healthcare
June 2, 2026 at 15:30 UTC
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company that discovers, develops, and supplies therapies for serious diseases addressed by targeted approaches. Research is organized around human biology and validated mechanisms, and programs move from early studies to practice with a focus on clear labeling and safe administration. Manufacturing is built for reproducible output and steady availability once a therapy enters routine care. Medical information and field support help clinicians apply guidance without breaking normal workflow. Regional teams manage access within local frameworks, while global functions keep quality and data safeguards aligned. In the healthcare sector and its partner ecosystem, the company positions itself as a long-term supplier that prioritizes continuity for providers and patients.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Vertex Pharmaceuticals's Technical Indicators Summary
VX1.DE is technically tilted bearish with short-term momentum losing ground and the price trading below several short and medium EMAs as well as the 200-period average, underscoring downward bias. The ADX remains low, indicating a lack of strong trending conviction, while ATR shows contained volatility and on-balance-volume reads are mixed, offering little buying support. The classic pivot sits above the market, highlighting resistance on any near-term bounce. Technical takeaway: indicators favor a continued bearish tone amid weak trend strength and negative momentum.
| Indicator | Value |
|---|---|
RSI (14) | 43.83 |
Stochastic %K (14, 3, 3) | 28.99 |
CCI (20) | -77.57 |
WPR (14) | -100.00 |
Momentum (10) | -12.85 |
MFI | 63.23 |
MACD Level (12, 26) | -0.09 |
Bollinger Bands | $359.42 - $390.56 |
ATR (14) | $7.32 (1.99%) |
ADX (14) | 13.27 |
OBV | -33,772 |
Classic Pivot Point | $377.27 |
Fibonacci Pivot Point | $377.27 |
Simple Moving Averages | $374.99 - $375.30(5 indicators) |
Exponential Moving Averages | $375.08 - $381.33(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Into the bell, a small sector dip of -0.87% left a soft macro backdrop for VX1d. The session wrapped with VX1d trading on very thin volume, only 0.07× average. End-of-day, VX1d still looked relatively defensive with a beta of 0.30.
Price Change
from €369.1 close
-€1.95
Trading Volume
Below avg (96)
7
vs S&P 500 Today
Strong Underperformance
-4.19%
52-Week Position
Mid-range
46.8%
Updated: June 2, 2026 at 15:01 UTC
Quote Summary
VX1d Headlines
Biotech ETFs Flash Classic Reversal Signal
April 1, 2026
Executives File New SEC Form 144 Sales
February 27, 2026